Main Menu

Five Prime Therapeutics, Inc.


Rigrodsky Law, P.A. is investigating Five Prime Therapeutics, Inc. (“Five Prime”) regarding possible breaches of fiduciary duties and other violations of law related to Five Prime’s agreement to be acquired by Amgen Inc.  Under the terms of the agreement, Five Prime’s shareholders will receive $38.00 in cash per share.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 04/13/2021

* Indicates a required field.

Back to Page